Patent EP0243204A2 successfully refreshed from Google Patents.
EP0243204A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Infective drug delivery system
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1987-04-24
•
Granted: —
•
Expires: 2007-04-24
Abstract
Abstract A drug delivery virion which contains an expression system for the desired protein active ingredient packaged in an envelope derived from a retrovirus is especially useful in administering materials which need to cross cell membranes in order to serve their function.
Inventors
- 👤 Francis P. Mccormick
- 👤 Michael Kriegler
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-03 04:35
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61P; A61P35/00; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/525; C12N7/00; A61K; A61K38/00; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/13011; C12N2740/13041; C12N2740/13043; C12N2740/13051; C12N2740/13052; C12N2740/13061; C12N2740/13062
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
53 words
A virion effective in drug delivery which comprises an RNA genome, wherein the genome comprises an mRNA encoding a protein drug and which mRNA is operably linked to control sequences and to a packaging site derived from a retrovirus, said genome contained in an envelope protein capable of infecting a target subject cell.
Claim 2
Dependent Claim
53 words
A virion effective in drug delivery which comprises an RNA genome, wherein the genome comprises an mRNA encoding a protein drug and which mRNA is operably linked to control sequences and to a packaging site derived from a retrovirus, said genome contained in an envelope protein capable of infecting a target subject cell.
Claim 3
Dependent Claim
53 words
The drug delivery virion of claim 1 wherein the protein drug is TNF, the control sequences and packaging site are derived from MoMLV, the control sequences are altered by replacing the MoMLV splice donor site with a sequence from HaSV, and wherein the envelope protein is capable of effecting infection of human cells.
Claim 4
Dependent Claim
37 words
A proviral DNA comprising a sequence encoding a desired protein drug operably linked to control sequences derived from a retrovirus, said DNA containing a Ψ packaging site and flanked by long terminal repeats derived from a retrovirus.
Claim 5
Dependent Claim
37 words
A proviral DNA comprising a sequence encoding a desired protein drug operably linked to control sequences derived from a retrovirus, said DNA containing a Ψ packaging site and flanked by long terminal repeats derived from a retrovirus.
Claim 6
Dependent Claim
17 words
An RNA sequence which comprises mRNA encoding a desired nonviral protein operably linked to retroviral control sequences.
Claim 7
Dependent Claim
17 words
An RNA sequence which comprises mRNA encoding a desired nonviral protein operably linked to retroviral control sequences.
Claim 8
Dependent Claim
24 words
A provirion encoding a desired nonviral protein which is ligated between two long terminal repeats derived from retrovirus, and containing a Ψ packaging site.
Claim 9
Dependent Claim
24 words
A provirion encoding a desired nonviral protein which is ligated between two long terminal repeats derived from retrovirus, and containing a Ψ packaging site.
Claim 10
Dependent Claim
17 words
A Ψ packaging site-deficient retroviral transformed cell line which is transfected with the provirion of claim 5.
Claim 11
Dependent Claim
22 words
A method to prepare a drug delivery virion which comprises culturing the cells of claim 6 and recovering the delivery virions produced.
Claim 12
Dependent Claim
19 words
A pharmaceutical composition which comprises the drug delivery virion of claim 1, which composition is free of wild-type virions.
Claim 13
Dependent Claim
51 words
The pharmaceutical composition of claim 8 wherein the protein drug is TNF, the control sequences and packaging site are derived from MoMLV, the control sequences are altered by replacing the MoMLV splice donor site with a sequence from HaSV, and the envelope protein is capable of effecting infection of human cells.
Claim 14
Dependent Claim
95 words
The use of:- (a) a proviral DNA comprising a sequence encoding a desired protein drug operably linked to control sequences derived from a retrovirus, said DNA containing a Ψ packaging site and flanked by long terminal repeats derived from a retrovirus; or (b) an RNA sequence which comprises mRNA encoding a desired nonviral protein operably linked to retroviral control sequences; or (c) a provirion encoding a desired nonviral protein which is ligated between two long terminal repeats derived from a retrovirus and containing a Ψ packaging site in the production of a drug delivery system.
Claim 15
Dependent Claim
95 words
The use of:- (a) a proviral DNA comprising a sequence encoding a desired protein drug operably linked to control sequences derived from a retrovirus, said DNA containing a Ψ packaging site and flanked by long terminal repeats derived from a retrovirus; or (b) an RNA sequence which comprises mRNA encoding a desired nonviral protein operably linked to retroviral control sequences; or (c) a provirion encoding a desired nonviral protein which is ligated between two long terminal repeats derived from a retrovirus and containing a Ψ packaging site in the production of a drug delivery system.
Claim 16
Independent Claim
52 words
A method of providing a drug delivery system which comprises providing a genome comprising an mRNA encoding a protein drug which mRNA is operably linked to control sequences and to a packaging site derived from a retrovirus and packaging the genome in an envelope protein capable of infecting a target subject cell.
Claim 17
Independent Claim
52 words
A method of providing a drug delivery system which comprises providing a genome comprising an mRNA encoding a protein drug which mRNA is operably linked to control sequences and to a packaging site derived from a retrovirus and packaging the genome in an envelope protein capable of infecting a target subject cell.
Claim 18
Independent Claim
90 words
A method for preparing a pharmaceutical composition which comprises providing a genome comprising an mRNA encoding a protein drug and which mRNA is operably linked to control sequences and to a packaging site derived from a retrovirus, and packaging the genome in an envelope protein capable of infecting a target subject cell so as to avoid wild-type virions by transfecting a Ψ packaging site-deficient retroviral transformed cell line with a provirion encoding the drug ligated between two long terminal repeats derived from a retrovirus and containing a Ψ packaging site.
Claim 19
Independent Claim
90 words
A method for preparing a pharmaceutical composition which comprises providing a genome comprising an mRNA encoding a protein drug and which mRNA is operably linked to control sequences and to a packaging site derived from a retrovirus, and packaging the genome in an envelope protein capable of infecting a target subject cell so as to avoid wild-type virions by transfecting a Ψ packaging site-deficient retroviral transformed cell line with a provirion encoding the drug ligated between two long terminal repeats derived from a retrovirus and containing a Ψ packaging site.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.